JP2006524246A5 - - Google Patents

Download PDF

Info

Publication number
JP2006524246A5
JP2006524246A5 JP2006510017A JP2006510017A JP2006524246A5 JP 2006524246 A5 JP2006524246 A5 JP 2006524246A5 JP 2006510017 A JP2006510017 A JP 2006510017A JP 2006510017 A JP2006510017 A JP 2006510017A JP 2006524246 A5 JP2006524246 A5 JP 2006524246A5
Authority
JP
Japan
Prior art keywords
cancer
neoplasm
pharmaceutical composition
composition according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006510017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006524246A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/011458 external-priority patent/WO2004093854A2/en
Publication of JP2006524246A publication Critical patent/JP2006524246A/ja
Publication of JP2006524246A5 publication Critical patent/JP2006524246A5/ja
Pending legal-status Critical Current

Links

JP2006510017A 2003-04-22 2004-04-14 抗新生物組み合わせ Pending JP2006524246A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46449803P 2003-04-22 2003-04-22
PCT/US2004/011458 WO2004093854A2 (en) 2003-04-22 2004-04-14 Antineoplastic combinations

Publications (2)

Publication Number Publication Date
JP2006524246A JP2006524246A (ja) 2006-10-26
JP2006524246A5 true JP2006524246A5 (https=) 2007-06-07

Family

ID=33310901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006510017A Pending JP2006524246A (ja) 2003-04-22 2004-04-14 抗新生物組み合わせ

Country Status (26)

Country Link
US (1) US20040258662A1 (https=)
EP (1) EP1615640B1 (https=)
JP (1) JP2006524246A (https=)
KR (1) KR20060006058A (https=)
CN (1) CN1777424A (https=)
AR (1) AR044039A1 (https=)
AT (1) ATE352301T1 (https=)
AU (1) AU2004231720A1 (https=)
BR (1) BRPI0409632A (https=)
CA (1) CA2519338A1 (https=)
CL (1) CL2004000836A1 (https=)
CO (1) CO5630033A2 (https=)
CR (1) CR7993A (https=)
DE (1) DE602004004520T2 (https=)
DK (1) DK1615640T3 (https=)
EC (1) ECSP056114A (https=)
ES (1) ES2279407T3 (https=)
MX (1) MXPA05010582A (https=)
NO (1) NO20054412L (https=)
PL (1) PL1615640T3 (https=)
PT (1) PT1615640E (https=)
RU (1) RU2005136222A (https=)
TW (1) TW200503753A (https=)
UA (1) UA80756C2 (https=)
WO (1) WO2004093854A2 (https=)
ZA (1) ZA200508574B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
ES2364495T3 (es) 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.
AU2006222500B2 (en) * 2005-03-07 2011-09-01 Robarts Research Institute Use of a combination of Myxoma virus and rapamycin for therapeutic treatment
JP2009514870A (ja) 2005-11-04 2009-04-09 ワイス mTORインヒビター、ハーセプチン、および/またはHKI−272の抗悪性腫瘍性組み合わせ
US20070116757A1 (en) * 2005-11-08 2007-05-24 Collegium Pharmaceutical, Inc. Methylene Blue Derivatives
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN105147713A (zh) 2008-08-04 2015-12-16 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
SG174382A1 (en) 2009-04-06 2011-11-28 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
US9278090B2 (en) * 2012-09-05 2016-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preventing the development of mucositis and related disorders

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
JP2004507465A (ja) * 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US7560425B2 (en) * 2002-06-07 2009-07-14 Waratah Pharmaceuticals Inc. Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes
DE60324609D1 (de) * 2002-09-17 2008-12-18 Wyeth Corp GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779

Similar Documents

Publication Publication Date Title
JP2006524246A5 (https=)
JP2006519862A5 (https=)
RU2005130767A (ru) Противоопухолевые композиции, содержащие производное рапамицина и ингибитор ароматазы
RU2005136222A (ru) Противоопухолевые комбинации
JP2025065346A5 (ja) 組み合わせ物
JP2019521087A5 (https=)
JP2009514870A5 (https=)
JP2006515883A5 (https=)
ES2705529T3 (es) Tratamiento combinatorio del cáncer
TWI641374B (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
JP2019506403A5 (https=)
JP2019510832A5 (https=)
RU2018105655A (ru) Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака
RU2013131004A (ru) Комбинация (а) ингибитора фосфоинозит-3-киназы и (б) модулятора пути ras/raf/mek
RU2020114632A (ru) Терапевтические способы, относящиеся к ингибиторам hsp90
RU2010142390A (ru) Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения
JP2014512356A5 (https=)
JP2004525950A5 (https=)
JP2016535756A5 (https=)
RU2010151428A (ru) Пероральные составы, содержащие аналоги цитидина, и способы их использования
CN102065865B (zh) 多发性骨髓瘤治疗
JP2014518544A5 (https=)
JP2021511372A5 (https=)
JP2003533485A5 (https=)
JP2004532883A5 (https=)